

Applicant : Fred S. Lamb
Serial No. : 09/512,926
Filed : February 25, 2000
Page : 2 of 9

Attorney's Docket No.: 17023-010001/N9-19

Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the application.


Listing of Claims

1. (Previously Presented) A method to normalize the contractile response of vasculature in a patient in need of such normalization, the vasculature comprising a vascular smooth muscle cell layer and a compromised endothelial cell layer, wherein the method comprises administering a pharmaceutically effective amount of a CLC3 blocker, or a pharmaceutically acceptable salt thereof.
- 2-5. (Canceled)
6. (Previously Presented) A method of claim 23, wherein the compound administered is 1-p- β -dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene, or a pharmaceutically acceptable salt thereof.
7. (Previously Presented) A method of claim 23, wherein the patient has diabetes.
8. (Previously Presented) A method of claim 23, wherein the patient has had a surgical procedure.
9. (Previously Presented) A method of claim 23, wherein the patient has hypertension.
10. (Previously Presented) A method of claim 23, wherein the patient has coronary artery disease.
11. (Previously Presented) A method of claim 23, which further comprises administering a pharmaceutically-effective compound selected from the group consisting of: an anti-diabetes agent; an anti-hypertension agent; an anti-coronary artery disease agent; and an anti-restenosis agent.
- 12-22. (Canceled)

Applicant : Fred S. Lamb
 Serial No. : 09/512,926
 Filed : February 25, 2000
 Page : 3 of 9

Attorney's Docket No.: 17023-010001/N9-19

23. (Previously Presented) A method of claim 1, wherein the CLC3 blocker is a compound of Formula I



wherein

either R^4 is H or a lower alkyl radical and R^5 is a lower alkyl radical, or R^4 and R^5 are joined together with the adjacent nitrogen atom to form a heterocyclic radical;

R^6 is H or a lower alkyl radical;

R^7 is H, halo, OH, a lower alkyl radical, or is a buta-1,3-dienyl radical which together with the adjacent benzene ring forms a naphthyl radical;

R^8 is H or OH; and

n is 2;

or a pharmaceutically acceptable salt thereof.

24. (Canceled)

25. (Previously Presented) A method to normalize the contractile response of vasculature in response to a vasoconstrictor agonist in a patient in need of such normalization, the vasculature comprising a vascular smooth muscle cell layer and a compromised endothelial cell layer, wherein the method comprises administering a pharmaceutically effective amount of a CLC3 blocker, or a pharmaceutically acceptable salt thereof, and wherein the vasoconstrictor agonist is norepinephrine.